Insider Selling: Sight Sciences, Inc. (NASDAQ:SGHT) Insider Sells $11,647.02 in Stock

Sight Sciences, Inc. (NASDAQ:SGHT) insider Matthew Link sold 5,042 shares of the company’s stock in a transaction that occurred on Wednesday, April 2nd. The stock was sold at an average price of $2.31, for a total value of $11,647.02. Following the completion of the sale, the insider now owns 830,551 shares of the company’s stock, valued at $1,918,572.81. This trade represents a 0.60 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Sight Sciences Stock Performance

Sight Sciences stock opened at $2.30 on Friday. The company has a debt-to-equity ratio of 0.36, a current ratio of 10.18 and a quick ratio of 9.74. The company has a market cap of $118.07 million, a P/E ratio of -2.25 and a beta of 2.46. Sight Sciences, Inc. has a fifty-two week low of $2.04 and a fifty-two week high of $8.45. The firm’s 50 day simple moving average is $2.67 and its 200-day simple moving average is $3.84.

Sight Sciences (NASDAQ:SGHT) last announced its earnings results on Wednesday, March 5th. The company reported ($0.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by ($0.01). The firm had revenue of $19.07 million for the quarter, compared to analyst estimates of $18.98 million. Sight Sciences had a negative net margin of 63.30% and a negative return on equity of 47.28%. During the same period last year, the firm earned ($0.22) earnings per share. As a group, equities research analysts predict that Sight Sciences, Inc. will post -0.99 EPS for the current year.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on SGHT. UBS Group cut their price objective on Sight Sciences from $5.50 to $5.00 and set a “buy” rating for the company in a report on Monday, January 27th. Stifel Nicolaus reduced their price objective on shares of Sight Sciences from $5.00 to $4.00 and set a “buy” rating for the company in a research report on Thursday, March 6th. Piper Sandler dropped their target price on shares of Sight Sciences from $5.50 to $3.50 and set a “neutral” rating on the stock in a report on Thursday, March 6th. Needham & Company LLC restated a “hold” rating on shares of Sight Sciences in a report on Thursday, March 6th. Finally, Citigroup dropped their price target on Sight Sciences from $4.60 to $3.00 and set a “neutral” rating on the stock in a report on Tuesday, March 4th. Five investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $3.83.

Institutional Investors Weigh In On Sight Sciences

Several hedge funds have recently bought and sold shares of the business. ProShare Advisors LLC purchased a new stake in shares of Sight Sciences in the fourth quarter worth approximately $36,000. Dynamic Technology Lab Private Ltd purchased a new stake in Sight Sciences in the 4th quarter worth approximately $40,000. Arkadios Wealth Advisors acquired a new stake in shares of Sight Sciences during the 4th quarter valued at $47,000. WealthTrust Asset Management LLC purchased a new position in shares of Sight Sciences during the 4th quarter valued at $48,000. Finally, Mitsubishi UFJ Asset Management Co. Ltd. purchased a new stake in shares of Sight Sciences during the fourth quarter worth $50,000. 55.51% of the stock is owned by hedge funds and other institutional investors.

About Sight Sciences

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.